KFDA approves Effient, blood-thinning medication

Published: 2010-08-05 06:58:00

Updated: 2010-08-05 06:58:00

The Korea Food and Drug Administration approved a blood-thinning drug Effient tablets (prasugrel), co-developed by Eli-Lilly and Daiich Sankyo, on July 29 to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK